Home » Stocks » ZGNX

Zogenix, Inc. (ZGNX)

Stock Price: $21.49 USD -0.67 (-3.02%)
Updated Feb 26, 2021 3:47 PM EST - Market open
Market Cap 1.23B
Revenue (ttm) 7.09M
Net Income (ttm) -195.27M
Shares Out 55.55M
EPS (ttm) -3.84
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $21.49
Previous Close $22.16
Change ($) -0.67
Change (%) -3.02%
Day's Open 21.70
Day's Range 20.04 - 22.39
Day's Volume 752,540
52-Week Range 16.65 - 32.42

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 23 hours ago

EMERYVILLE, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today provided a corpora...

Zacks Investment Research - 1 week ago

Zogenix (ZGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 2 weeks ago

EMERYVILLE, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it will report its fina...

GlobeNewsWire - 3 weeks ago

EMERYVILLE, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, announced today that FINTEPLA® (fenfluramine...

GlobeNewsWire - 1 month ago

EMERYVILLE, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today reported select pr...

24/7 Wall Street - 2 months ago

After an incredibly wild and wooly year for investors, many across Wall Street are cautiously optimistic for 2021.

Other stocks mentioned: ACAD, NBIX, QURE, VRTX
GlobeNewsWire - 2 months ago

EMERYVILLE, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, announced today that the European Commission...

PRNewsWire - 2 months ago

CAMBRIDGE, Mass. and EMERYVILLE, Calif., Dec. 3, 2020 /PRNewswire/ -- Tevard Biosciences, a privately-held biotechnology company pioneering tRNA-based gene therapies, and Zogenix (Nasdaq: ZGNX...

Forbes - 2 months ago

As COVID surges to unprecedented levels with additional shutdown measures taking place, markets declined to close what has been a largely strong November. Using our deep learning algorithms, o...

Other stocks mentioned: CALM, CRNC, TPIC, TRUP
Seeking Alpha - 3 months ago

Zogenix just launched Fintepla, a product to treat Dravet syndrome. GW Pharma already has a Fintepla competitor Epidiolex approved and growing big sales in Dravet syndrome and other indication...

Seeking Alpha - 3 months ago

Zogenix's (ZGNX) CEO Stephen Farr on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Zogenix (ZGNX) delivered earnings and revenue surprises of -0.99% and 50.05%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 3 months ago

EMERYVILLE, Calif. , Nov. 09, 2020 (GLOBE NEWSWIRE) --  Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced financ...

Zacks Investment Research - 3 months ago

Zogenix (ZGNX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Insider Monkey - 3 months ago

In this article we will take a look at whether hedge funds think Zogenix, Inc. (NASDAQ:ZGNX) is a good investment right now. We check hedge fund and billionaire investor sentiment before delvi...

Zacks Investment Research - 3 months ago

Zogenix (ZGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 3 months ago

EMERYVILLE, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it has changed th...

Seeking Alpha - 4 months ago

Shares of Zogenix have been under pressure lately due to safety concerns surrounding its unique anti-epileptic drug, Fintepla. Despite receiving FDA approval for a rare and serious epileptic c...

GlobeNewsWire - 4 months ago

EMERYVILLE, Calif., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that the Committee for Medic...

GlobeNewsWire - 4 months ago

EMERYVILLE, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a global biopharmaceutical company developing rare disease therapies, shared new data analyses for FINTEPLA®...

GlobeNewsWire - 4 months ago

EMERYVILLE, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that the initial purch...

GlobeNewsWire - 4 months ago

EMERYVILLE, Calif., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, and its subsidiary...

Seeking Alpha - 4 months ago

Thesis that FDA approval of Fintepla would immediately unlock value was wrong. With ZGNX down nearly 40% since, and the story still fully intact, the stock is now highly attractive.

GlobeNewsWire - 5 months ago

EMERYVILLE, Calif., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX) today announced the pricing of its offering of $200,000,000 aggregate principal amount of 2.75% convertibl...

GlobeNewsWire - 5 months ago

EMERYVILLE, Calif., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX) today announced its intention to offer, subject to market and other conditions, $200,000,000 aggregate pri...

GlobeNewsWire - 5 months ago

Correction: In this updated news release issued September 21, 2020 by Zogenix, Inc, the name of the organization, WorldWideWomen, has been corrected. The full corrected press release follows.

GlobeNewsWire - 5 months ago

EMERYVILLE, Calif., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced the a...

GlobeNewsWire - 5 months ago

EMERYVILLE, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today reported positi...

Seeking Alpha - 6 months ago

Zogenix's (ZGNX) CEO Stephen Farr on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Zogenix (ZGNX) delivered earnings and revenue surprises of 5.88% and -6.18%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 6 months ago

EMERYVILLE, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced...

GlobeNewsWire - 6 months ago

EMERYVILLE, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its...

Zacks Investment Research - 6 months ago

Zogenix (ZGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GuruFocus - 7 months ago

It’s been a bumpy ride for Zogenix Inc. (NASDAQ:ZGNX) shareholders over the past three years, but at just more than $29, the stock is well below its average 12-month price target of $44.60.

Zacks Investment Research - 7 months ago

Zogenix (ZGNX) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Seeking Alpha - 7 months ago

Zogenix: Market Reaction To Fintepla's Approval Offers A Gift To Investors

Market Watch - 7 months ago

Shares of Zogenix Inc. ZGNX, -9.42% gained 2.9% in premarket trading on Monday, following the news on Friday that the Food and Drug Administration had approved Fintepla, its treatment for seiz...

Zacks Investment Research - 8 months ago

Zogenix (ZGNX) gets FDA nod for Fintepla oral solution, CIV for the treatment of seizures associated with Dravet Syndrome in patients 2 years of age or older.

PRNewsWire - 8 months ago

EMERYVILLE, Calif., June 25, 2020 /PRNewswire/ -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that the U.S. Food and Drug A...

GlobeNewsWire - 8 months ago

EMERYVILLE, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that the U.S. Food and ...

Benzinga - 8 months ago

The SPDR S&P 500 (NYSE: SPY) started off the week on a high note on Monday morning after a turbulent week of trading last week.

Other stocks mentioned: ARDS, CGC, DB, DRI, HSBC, KPTI, NKE, UBS
Zacks Investment Research - 8 months ago

Investors need to pay close attention to Zogenix (ZGNX) stock based on the movements in the options market lately.

GlobeNewsWire - 8 months ago

New materials were created in collaboration with the Dravet Syndrome Foundation to support and celebrate the brothers and sisters of those living with a rare and severe epilepsy New materials ...

Seeking Alpha - 9 months ago

The long-awaited PDUFA date for Zogenix's lead drug, Fintepla® is approaching with the FDA timeline pushback earlier this year offering a favorable entry point into the stock.

GlobeNewsWire - 9 months ago

Unique tips and tools informed by the Dravet syndrome community are designed to help parents and siblings of a child with Dravet stay positive and connected. Unique tips and tools informed by ...

Seeking Alpha - 9 months ago

Zogenix, Inc. (ZGNX) CEO Stephen Farr on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

Zogenix (ZGNX) delivered earnings and revenue surprises of 35.19% and 24.90%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 9 months ago

Zogenix (ZGNX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

GlobeNewsWire - 10 months ago

New in-house role will lead Zogenix Legal team and serve as a member of the Executive Team New in-house role will lead Zogenix Legal team and serve as a member of the Executive Team

Zacks Investment Research - 10 months ago

Zogenix (ZGNX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

About ZGNX

Zogenix, a pharmaceutical company, develops and commercializes transformative therapies to enhance the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome (LGS); and which is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It also developing MT1621, an investigati... [Read more...]

Industry
Biotechnology
IPO Date
Nov 23, 2010
CEO
Stephen Farr
Employees
141
Stock Exchange
NASDAQ
Ticker Symbol
ZGNX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 13 analysts, the average rating for Zogenix stock is "Buy." The 12-month stock price forecast is 49.60, which is an increase of 130.81% from the latest price.

Price Target
$49.60
(130.81% upside)
Analyst Consensus: Buy